Follow the people · Insider
Berndt Modig
Berndt Modig files insider transactions with the SEC as a chief executive officer of Pharvaris (PHVS). We hold 6 disclosed purchases and sales filed since 3 May 2016, 3 of them in the last 90 days.
- Files forPHVS
- Disclosed buys and sells6 in all, 3 in the last 90 days
- Last disclosure18 August 2026
Positions held
4 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 9 April 2026 — 14 August 2026Chief Executive Officer · Pharvaris (PHVS)8 Form 4 lines · source: SEC Form 4
- Filed 15 April 2021 — 15 April 2021Director · Sio Gene Therapies (SIOX)1 Form 4 line · source: SEC Form 4
- Filed 15 April 2019 — 15 April 2020Director · Axovant Sciences (AXGT)2 Form 4 lines · source: SEC Form 4
- Filed 29 April 2016 — 15 March 2018Director · Axovant Sciences (AXON)5 Form 4 lines · source: SEC Form 4
Everything they disclosed
16 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 2,292 shares of PharvarisSEC Form 418 August 2026Common Stock · traded 14 August 2026 · filed 18 August 2026
- ▼ sold on the open market 2,292 shares of PharvarisSEC Form 415 July 2026Common Stock · traded 13 July 2026 · filed 15 July 2026
- ▼ sold on the open market 2,191 shares of PharvarisSEC Form 417 June 2026Common Stock · traded 15 June 2026 · filed 17 June 2026
- ▼ sold on the open market 100 shares of PharvarisSEC Form 417 June 2026Common Stock · traded 15 June 2026 · filed 17 June 2026
- ▼ sold on the open market 2,292 shares of PharvarisSEC Form 420 May 2026Common Stock · traded 18 May 2026 · filed 20 May 2026
- ▼ sold on the open market 2,292 shares of PharvarisSEC Form 420 April 2026Common Stock · traded 16 April 2026 · filed 20 April 2026
- ▼ sold on the open market 23,133 shares of PharvarisSEC Form 410 April 2026Common Stock · traded 9 April 2026 · filed 10 April 2026
- ▼ sold on the open market 200 shares of PharvarisSEC Form 410 April 2026Common Stock · traded 9 April 2026 · filed 10 April 2026
- was granted 42,000 shares of Sio Gene Therapies (a derivative holding)SEC Form 419 April 2021Stock Option (Right to Buy) · traded 15 April 2021 · filed 19 April 2021
- was granted 17,500 shares of Axovant Gene Therapies (a derivative holding)SEC Form 417 April 2020Stock Option (Right to Buy) · traded 15 April 2020 · filed 17 April 2020
- was granted 255,000 shares of Axovant Sciences (a derivative holding)SEC Form 417 April 2019Stock Option (Right to Buy) · traded 15 April 2019 · filed 17 April 2019
- was granted 75,000 shares of Axovant Sciences (a derivative holding)SEC Form 416 March 2018Stock Option (Right to Buy) · traded 15 March 2018 · filed 16 March 2018
- exercised options over 77,914 shares of Axovant SciencesSEC Form 43 January 2018Common Stock · traded 29 December 2017 · filed 3 January 2018
- exercised options over 77,914 shares of Axovant Sciences (a derivative holding)SEC Form 43 January 2018Stock Option (right to buy) · traded 29 December 2017 · filed 3 January 2018
- was granted 27,000 shares of Axovant Sciences (a derivative holding)SEC Form 42 May 2017Stock Option (Right to Buy) · traded 28 April 2017 · filed 2 May 2017
- was granted 47,000 shares of Axovant Sciences (a derivative holding)SEC Form 43 May 2016Stock Option (Right to Buy) · traded 29 April 2016 · filed 3 May 2016
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.